Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07780383 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Primary endpoints: details revised at 2 of 12 entries · Trial sites expanded: 1 → 6 locations · Eligibility criteria expanded, about 10 words · 1 more Show 4 more changesShow less
    • Primary endpoints: details revised at 2 of 12 entries
    • Trial sites expanded: 1 → 6 locations
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 3 of 20 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration
Trial Details
NCT Number NCT07780383
Lead Sponsor Bristol-Myers Squibb
Conditions Alzheimer's Disease, Healthy Participants
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov